Article Listing - Healthy revenue growth at Gilead

PHARMA ECONOMICS' "SEVEN DEADLY SINS"

13 April 1992

Concerns about economic evaluation of new drug products have been likened to the seven deadly sins by Michael Drummond of...

SAFER TRAVELLER'S DIARRHEA DRUG

13 April 1992

A safer treatment for traveller's diarrhea may soon be available, which will be suitable for use by adults, children and...

FORTHCOMING MEETINGS

13 April 1992

Pharmaceutical industry meetings to be held in London by Management Forum shortly include:

- Improving Drug Development: Principles and Practice of...

UPJOHN UPDATES ON R&D PROGRESS

13 April 1992

As the 1990s progress, US pharmaceutical company Upjohn faces a situation where several of its high-earning products will come to...

PROMISING ALZHEIMER'S PROGRAM FROM ATHENA

13 April 1992

In the current explosion of neurology research and development, the US company, Athena Neurosciences, is considered to be one of...

ZOVIRAX AND SHINGLES

13 April 1992

Wellcome's Zovirax (aciclovir) should only be used to treat shingles if patients are immunocompromised, according to the UK Medicines...

EPO AND HISTAMINE

13 April 1992

Recombinant erythropoietin therapy lowers plasma histamine concentrations in patients with uremia and can result in marked improvement of pruritus, according...

HOECHST JAPAN MERGERS?

13 April 1992

Hoechst Japan Ltd has proposed that in order to strengthen its operation in the next five years it will examine...

CERVOXAN 60mg LAUNCHED IN FRANCE

13 April 1992

Laboratoires Sobio, which is part of SmithKline Beecham, has launched a new 60mg oral formulation of Cervoxan (vinburnine) its cerebral/peripheral...

ROCHE'S LOCERYL LAUNCHED IN FRANCE

13 April 1992

Roche Produits, a subsidiary of Hoffmann-La Roche, has introduced its nail lacquer antifungal product Loceryl (amorolfine). This is the first...